News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
134,647 Results
Type
Article (6834)
Company Profile (82)
Press Release (127731)
Multimedia
Podcasts (2)
Webinars (4)
Section
Business (43815)
Career Advice (153)
Deals (6091)
Drug Delivery (9)
Drug Development (19417)
Employer Resources (15)
FDA (1931)
Job Trends (3059)
News (69833)
Policy (3745)
Tag
2024 BioCapital Digital (4)
2024 BioForest Digital (2)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (3)
2024 Biotech Bay Standard (9)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (2)
2024 Genetown Digital (1)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (2)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
Academia (722)
Academic (1)
Accelerated approval (1)
Adcomms (1)
Allergies (11)
Alliances (15030)
ALS (18)
Alzheimer's disease (397)
Antibody-drug conjugate (ADC) (28)
Approvals (1972)
Artificial intelligence (125)
Autoimmune disease (8)
Automation (5)
Bankruptcy (37)
Best Places to Work (2748)
BIOSECURE Act (5)
Biosimilars (13)
Biotechnology (65)
Bladder cancer (12)
Brain cancer (8)
Breast cancer (93)
Cancer (683)
Cardiovascular disease (39)
Career advice (142)
Career pathing (8)
CAR-T (34)
Cell therapy (87)
Cervical cancer (4)
Clinical research (15616)
Collaboration (367)
Compensation (202)
Complete response letters (4)
COVID-19 (303)
CRISPR (16)
C-suite (75)
Cystic fibrosis (30)
Data (693)
Decentralized trials (1)
Denatured (2)
Depression (7)
Diabetes (64)
Diagnostics (880)
Digital health (3)
Diversity, equity & inclusion (4)
Drug discovery (73)
Drug pricing (3)
Drug shortages (1)
Duchenne muscular dystrophy (18)
Earnings (14273)
Editorial (4)
Employer branding (2)
Employer resources (13)
Events (21609)
Executive appointments (202)
FDA (2205)
Featured Employer (20)
Friedreich's ataxia (1)
Frontotemporal dementia (1)
Funding (221)
Gene editing (27)
Generative AI (13)
Gene therapy (65)
GLP-1 (161)
Government (378)
Guidances (15)
Healthcare (3131)
Huntington's disease (9)
IgA nephropathy (3)
Immunology and inflammation (29)
Indications (6)
Infectious disease (327)
Inflammatory bowel disease (45)
Inflation Reduction Act (1)
Influenza (7)
Intellectual property (21)
Interviews (18)
IPO (3066)
IRA (4)
Job creations (543)
Job search strategy (130)
Kidney cancer (3)
Labor market (7)
Layoffs (59)
Leadership (2)
Legal (598)
Liver cancer (13)
Lung cancer (100)
Lymphoma (46)
Machine learning (3)
Management (6)
Manufacturing (61)
MASH (6)
Medical device (900)
Medtech (901)
Mergers & acquisitions (3169)
Metabolic disorders (133)
Multiple sclerosis (14)
Neurodegenerative disease (25)
Neuroscience (535)
NextGen: Class of 2025 (983)
Non-profit (914)
Northern California (882)
Now hiring (6)
Obesity (66)
Opinion (44)
Ovarian cancer (23)
Pain (14)
Pancreatic cancer (26)
Parkinson's disease (45)
Partnered (6)
Patents (34)
Patient recruitment (21)
Peanut (5)
People (12949)
Pharmaceutical (13)
Phase I (5684)
Phase II (6646)
Phase III (4711)
Pipeline (356)
Policy (14)
Postmarket research (373)
Preclinical (2800)
Press Release (38)
Prostate cancer (26)
Psychedelics (1)
Radiopharmaceuticals (70)
Rare diseases (77)
Real estate (1073)
Recruiting (4)
Regulatory (3147)
Reports (12)
Research institute (893)
Resumes & cover letters (8)
Rett syndrome (2)
RNA editing (1)
RSV (7)
Schizophrenia (18)
Series A (41)
Series B (24)
Service/supplier (2)
Sickle cell disease (6)
Southern California (659)
Special edition (1)
Spinal muscular atrophy (77)
Sponsored (10)
Startups (1071)
Stomach cancer (1)
Supply chain (10)
Tariffs (2)
United States (5916)
Vaccines (78)
Venture capitalists (11)
Weight loss (24)
Women's health (3)
Worklife (3)
Date
Today (9)
Last 7 days (124)
Last 30 days (651)
Last 365 days (8933)
2025 (2485)
2024 (9502)
2023 (10072)
2022 (12201)
2021 (12588)
2020 (10620)
2019 (8404)
2018 (6317)
2017 (6887)
2016 (6183)
2015 (6895)
2014 (5002)
2013 (4040)
2012 (4450)
2011 (4798)
2010 (4504)
Location
Africa (115)
Alabama (12)
Alaska (3)
Arizona (15)
Arkansas (2)
Asia (9048)
Australia (1390)
California (1793)
Canada (446)
China (201)
Colorado (65)
Connecticut (111)
Delaware (89)
Europe (20806)
Florida (156)
Georgia (25)
Idaho (5)
Illinois (100)
India (9)
Indiana (150)
Iowa (1)
Japan (73)
Kansas (9)
Kentucky (2)
Louisiana (2)
Maine (7)
Maryland (247)
Massachusetts (1446)
Michigan (17)
Minnesota (51)
Missouri (30)
Montana (11)
Nebraska (2)
Nevada (6)
New Hampshire (7)
New Jersey (440)
New Mexico (12)
New York (389)
North Carolina (179)
North Dakota (2)
Northern California (882)
Ohio (43)
Oklahoma (5)
Oregon (5)
Pennsylvania (231)
Puerto Rico (1)
Rhode Island (10)
South America (145)
South Carolina (3)
Southern California (659)
Tennessee (17)
Texas (204)
Utah (41)
Virginia (34)
Washington D.C. (11)
Washington State (120)
Wisconsin (22)
134,647 Results for "c4x discovery".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 3, 2025
February 4, 2025
·
1 min read
C4X Discovery Holdings PLC Announces Divestment of Orexin-1 to Indivior for £15.95m
C4X Discovery Holdings plc, a pioneering Drug Discovery company, announces the execution of an asset purchase agreement for Indivior PLC to acquire the proprietary rights to C4XD’s oral Orexin-1 receptor antagonist, C4X_3256 for substance use disorder, for £15.95 million.
August 1, 2023
·
4 min read
Press Releases
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 3, 2024
December 4, 2024
·
1 min read
Genetown
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
X4 Pharmaceuticals today announced that management will be participating in the upcoming H.C. Wainwright 2nd Annual BioConnect Investor Conference, taking place on May 20th, 2024, at the Nasdaq Stock Exchange in New York City.
May 13, 2024
·
1 min read
Press Releases
C4X Discovery Holdings Limited announces progress on immuno-inflammation programmes and appointment of new Board members
July 22, 2024
·
6 min read
Press Releases
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2024
·
1 min read
Press Releases
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 1, 2024
November 4, 2024
·
1 min read
Press Releases
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 3, 2024
September 4, 2024
·
1 min read
Press Releases
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 1, 2024
August 2, 2024
·
1 min read
Business
AstraZeneca and C4X Discovery Ink $402M COPD Collaboration
C4X entered into a licensing deal with AstraZeneca to develop an oral treatment for COPD and other inflammatory and respiratory illnesses that could reach $402 million.
November 28, 2022
·
2 min read
·
Mark Terry
1 of 13,465
Next
